[B-cell-targeted therapy in the treatment of autoimmune diseases]. / B-Zell-gerichtete Therapie bei Autoimmunerkrankungen.
Z Rheumatol
; 68(3): 255-9, 2009 May.
Article
in De
| MEDLINE
| ID: mdl-19384549
ABSTRACT
In recent years a growing body of evidence suggests a more central role for B-cells in the pathogenesis of several autoimmune diseases, apart from being the precursors of autoantibody-producing plasma cells. B-lymphocytes play an important role in the pathogenesis of various autoimmune diseases. In particular, the introduction of rituximab, a depleting antibody targeting CD20+ B cells and its clinical efficacy in rheumatoid arthritis, systemic lupus erythematosus, vasculitis and multiple sclerosis has stimulated further B-cell-targeted therapies. Other biologicals targeting CD20 are under clinical investigation. New strategies include targeting further B-cell surface markers such as CD22, as well as blocking B-cell-activating factors or their receptors.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Autoimmune Diseases
/
B-Lymphocytes
/
Drug Delivery Systems
/
Antirheumatic Agents
/
Antigens, CD20
Limits:
Animals
/
Humans
Language:
De
Journal:
Z Rheumatol
Year:
2009
Document type:
Article